<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03967548</url>
  </required_header>
  <id_info>
    <org_study_id>ZK-SFT-201909</org_study_id>
    <nct_id>NCT03967548</nct_id>
  </id_info>
  <brief_title>The Germinal Peptide Eye Drops in Healthy Volunteers in a Clinical Study</brief_title>
  <official_title>To Evaluate the Local Pharmacokinetic Characteristics of Single Administration of Germinal Peptide Eye Drops in Healthy Volunteers in a Phase I Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The subjects of this study were healthy subjects, who were given medicine in a single dose&#xD;
      group: 0.004%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tear collection was conducted on the single dose D1 (that is, the day of administration).&#xD;
      Collection points: 10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 12 h after&#xD;
      administration.Each time 5-50 mg (generally 20 mg), a total of 160-1600 mg of tears will be&#xD;
      collected (during the screening period, all subjects will retain the tear samples collected&#xD;
      by the Schirmer filter paper, among which, qualified tear samples will be used for blank&#xD;
      samples or methodological investigation.After administration, only 1 tear collection site&#xD;
      will be collected for each subject.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">May 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve （0-t）</measure>
    <time_frame>Within 12hours after administration</time_frame>
    <description>AUC（0-t）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under curve（0-∞）</measure>
    <time_frame>Within 12hours after administration</time_frame>
    <description>AUC（0-∞）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak concentration</measure>
    <time_frame>Within 12hours after administration</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak time</measure>
    <time_frame>Within 12hours after administration</time_frame>
    <description>Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life</measure>
    <time_frame>Within 12hours after administration</time_frame>
    <description>t1/2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution</measure>
    <time_frame>Within 12hours after administration</time_frame>
    <description>Vd</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination rate constant</measure>
    <time_frame>Within 12hours after administration</time_frame>
    <description>Kel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time</measure>
    <time_frame>Within 12hours after administration</time_frame>
    <description>MRT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance</measure>
    <time_frame>Within 12hours after administration</time_frame>
    <description>CL or CL/F</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Corneal Defect</condition>
  <arm_group>
    <arm_group_label>0.004% single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>96 subjects will be treated with Germinal peptide eye drops 0.004% single dose (16 were pre-tested and 64 were formally tested).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Germinal peptide eye drops</intervention_name>
    <description>Germinal peptide eye drops of 0.004%</description>
    <arm_group_label>0.004% single-dose</arm_group_label>
    <other_name>shengfatai-eye drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. healthy volunteers aged between 18 and 45, both male and female in each group;&#xD;
&#xD;
          2. body mass index between 19 and 26 kg/m2 (including critical value), male weight 50 kg,&#xD;
             female weight 45 kg;&#xD;
&#xD;
          3. target eye Schirmer Ⅰ test (Schirmer filter paper bending, clip next eyelid medial 1/3&#xD;
             conjunctival sac within 5 min) tear wet filter paper length or greater 10 mm;&#xD;
&#xD;
          4. subjects will participate in the study voluntarily and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. binocular corrected vision &lt; 1.0, abnormal intraocular pressure, slit lamp and fundus&#xD;
             examination with clinical significance;&#xD;
&#xD;
          2. those with abnormal physical examination, vital signs, electrocardiogram and&#xD;
             laboratory examination before the test with clinical significance;&#xD;
&#xD;
          3. patients with eye diseases, including history of inner eye surgery or laser surgery;&#xD;
&#xD;
          4. a medical history of central nervous system, spirit, cardiovascular system, kidney,&#xD;
             liver, respiratory system, metabolism system and skeletal muscle system, which may&#xD;
             endanger the safety of subjects or affect the results of the study;&#xD;
&#xD;
          5. positive test results of hepatitis b virus surface antigen (HBsAg), hepatitis c virus&#xD;
             antibody (hcv-ab), treponema pallidum specific antibody (tp-ab) or human&#xD;
             immunodeficiency virus antibody (hiv-p24 /Ab);&#xD;
&#xD;
          6. have a significant history of clinical allergy, especially drug allergy, especially&#xD;
             allergic to any component of germinal peptide eye drops;&#xD;
&#xD;
          7. smoking more than 5 cigarettes per day on average;&#xD;
&#xD;
          8. those who are suspected or have alcohol dependence, and their alcohol intake is more&#xD;
             than 2 units per day on average for 3 months (1 unit =10 mL ethanol, that is, 1 unit&#xD;
             =200 mL beer with 5% alcohol or 25 mL spirit with 40% alcohol or 83 mL wine with 12%&#xD;
             alcohol) or who have tested positive for alcohol;&#xD;
&#xD;
          9. history of drug abuse, or positive urine test of ketamine, morphine, methamphetamine,&#xD;
             dimethylene dioxyamphetamine, tetrahydrocannabinic acid;&#xD;
&#xD;
         10. have taken any medicine within 2 weeks before screening;&#xD;
&#xD;
         11. participated in clinical trials within the first 3 months of screening;&#xD;
&#xD;
         12. blood donation or blood loss 400 mL within 3 months before screening;&#xD;
&#xD;
         13. have used ophthalmic drugs or eyelash growth solution in the first 2 weeks;&#xD;
&#xD;
         14. select the subjects who have worn contact lenses or contact lenses in the first 2&#xD;
             weeks;&#xD;
&#xD;
         15. pregnant or lactating women and those planning to become pregnant (including male&#xD;
             subjects);No effective contraceptive measures were taken within 1 month prior to the&#xD;
             inclusion of subjects, or subjects (including male subjects) were unwilling to take&#xD;
             effective contraceptive measures within the next 6 months;&#xD;
&#xD;
         16. the researchers considered the participants unsuitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zhao, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiuli Zhao</name>
      <address>
        <city>Beijing</city>
        <zip>BJ10</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

